Trial Profile
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Ibrutinib (Primary) ; Ibrutinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RESOLVE
- Sponsors Pharmacyclics
- 01 Feb 2021 Results published in the Annals of Oncology
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database